Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 22,217 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Dry Eye
Interventions: Dexamethasone; Drug
Lead sponsor: Research Insight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Hemet, California • Laguna Hills, California • St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Stimulation-ON, Stimulation-OFF, Stimulation-ON Active Control; Device
Lead sponsor: Andrew Krystal; Other
Eligibility: 22 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2035
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Inflammatory Bowel Disease
Interventions: Definity; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: Diabetes, Hypertension, HIV
Interventions: HIV testing, General Health Screen; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Stroke, Depression, Anxiety, Coping Skills, Couples
Interventions: ReStoreD; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Venous Leg Ulcer
Interventions: Dermagraft(R), Profore; Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 34
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Ulcerative Colitis
Interventions: Etrasimod, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 62
States / cities: Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more

Conditions: E-cigarette Use, Substance Use
Interventions: ENDS Prevention Intervention (TBD); Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 10 Years to 14 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Child Rearing, Risk Reduction Behavior, Reproductive Behavior
Interventions: home visitation; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Female only
Enrollment: 604 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Anxiety, Depression, Depression, Anxiety, Anxiety Disorders
Interventions: Acceptance and Commitment Therapy (ACT), Reflective Journaling; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Malaria
Interventions: DM1157, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: EVT 201; Drug
Lead sponsor: Evotec Neurosciences GmbH; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: St. Petersburg, Florida • Atlanta, Georgia • Overland Park, Kansas + 2 more

Conditions: Mental Health, Burnout, Psychological
Interventions: Training; Behavioral
Lead sponsor: Colorado School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 519 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: erlotinib, onartuzumab, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Bakersfield, California • Fullerton, California • Long Beach, California + 11 more

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more

Conditions: Healthy, Living Kidney Donation
Interventions: Standard Care (in control arm), Telemedicine Shared Decision-Making; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Opiate Addiction
Interventions: Onsite treatment, Enhanced referral, Buprenorphine; Behavioral · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York

Conditions: NAFLD, NASH
Interventions: DD01, Placebo; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more

Conditions: Diabetes
Interventions: Saxagliptin, Placebo, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Columbiana, Alabama • Haleyville, Alabama • Mesa, Arizona + 45 more

Conditions: Surgery, Adolescent Behavior
Interventions: Behavioral Economics (BE) recruitment strategies, Biofeedback-based virtual reality (VR-BF), Manage My Pain; Behavioral · Other
Lead sponsor: Vanessa Olbrecht; Other
Eligibility: 12 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Depression
Interventions: Placebo, RO4917523; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Oceanside, California • San Diego, California • New Haven, Connecticut + 4 more

Search by objective public record fields.

The DEPOT Study (Dry Eye Prescription Options for Therapy)

Closed-Loop Deep Brain Stimulation for Major Depression

Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography

Platelet Rich Plasma Injections In Young And Old Human Subjects

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Project Wellness: Increasing HIV Testing Among West African Immigrants

Promoting Resilience in Stroke Survivor-carepartner Dyads (ReStoreD)

Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

The Development and Evaluation of a Culturally Grounded ENDS Intervention for Rural Hawaiian Youth

Age 6 Test of Home Visits by Nurses vs Paraprofessionals

Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

Efficacy Study of EVT 201 to Treat Insomnia

Workforce Mental Health Emergency Preparedness

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

Telemedicine to Support Living Kidney Donor Candidates

Onsite Buprenorphine Treatment at Syringe Exchange Programs

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Recruitment and Behavioral Economic Strategies

A Study of RO4917523 in Patients With Treatment Resistant Depression